Center-Authored Papers

Filters: Author is de Vos, Sven  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
February 2014
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A et al..  2014.  PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.. The New England journal of medicine. Abstract
Clinical Research Division
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A et al..  2014.  PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.. The New England journal of medicine. Abstract
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S et al..  2012.  Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(18):2183-2189. Abstract
Center-Authored Paper
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S et al..  2012.  Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(18):2183-2189. Abstract
April 2012
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S et al..  2012.  Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(18):2183-2189. Abstract
Apr 2012
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S et al..  2012.  Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(18):2183-2189. Abstract
2014
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A et al..  2014.  PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.. The New England journal of medicine. Abstract
2012
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S et al..  2012.  Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(18):2183-2189. Abstract